Radionuclide

Tampa General Hospital Opens Infusion Center at the TGH Cancer Institute's State-of-the-Art Satellite Location

Retrieved on: 
Wednesday, July 19, 2023
Proton, Tampa General Hospital, Travel, Accreditation, Drink, Ear, Indiana University Health Proton Therapy Center, Prescription, Nose, Hospital, Patient, ACS, Practitioner, American College, Health, News, Tissue, Bone marrow, Breast, HDR, Otorhinolaryngology, Liver, Skin, FCS, Cancer Institute, Radionuclide, COC, Cell, Radiopharmaceutical, Immunotherapy, Memorial Sloan Kettering Cancer Center, Research, University of Florida Cancer and Genetics Research Complex, Radiation, USF Health Byrd Alzheimer's Institute, Newsweek, Commission, Pharmacy, Radiation therapy, U.S. News & World Report, Physician, TGH, Proton therapy, Haematopoietic system, Throat, Nursing, Pharmaceutical industry, Medical imaging, Cancer, Oncology

TAMPA, Fla. , July 19, 2023 /PRNewswire/ -- In an endeavor to expand cancer care for the rapidly growing communities of south Hillsborough County, Tampa General Hospital (TGH) opened a state-of-the-art, 26-bay Infusion Center in the TGH Cancer Institute's Brandon location. A ribbon-cutting ceremony was held on July 19. Additionally, a Radiation Oncology Center will open at the Brandon location, 10740 Palm River Road, this fall.

Key Points: 
  • TAMPA, Fla. , July 19, 2023 /PRNewswire/ -- In an endeavor to expand cancer care for the rapidly growing communities of south Hillsborough County, Tampa General Hospital (TGH) opened a state-of-the-art, 26-bay Infusion Center in the TGH Cancer Institute's Brandon location.
  • "Our new TGH Cancer Institute location allows us to expand our reach and provide greater access to our community."
  • The TGH Cancer Institute satellite location in Brandon is part of Tampa General's $550 million master facility plan, the largest in the hospital's almost 100-year history.
  • The addition to the TGH Cancer Institute's Infusion Center will offer seven more chemotherapy areas for the treatment of cancer.

A Canadian lake holds the key to the beginning of the Anthropocene, a new geological epoch

Retrieved on: 
Tuesday, July 11, 2023
History of science, Max Planck Institute for Chemistry, Human, Anthropocene Working Group, Anthropocene, Native, Acceleration, Geology, International Commission on Stratigraphy, Great Acceleration, Pollen, Research, Radionuclide, Movement, Biodiversity, Haus der Kulturen der Welt, Population, World War II, Nature, GSSP, Atmosphere, Haus, Ecosystem, The Anthropocene Reviewed, Max Planck Society, Plutonium, Rare-earth element, Limestone, Uranium mining, Animal husbandry, Holocene, Crawford Lake Conservation Area

Leer en español Are we really living in the Anthropocene, the geological time marked by the global impact of human activity?

Key Points: 
  • Leer en español Are we really living in the Anthropocene, the geological time marked by the global impact of human activity?
  • What makes this site so special that it holds the dividing line between different geological epochs?

The footprint of the Great Acceleration

    • These studies have concluded that the Anthropocene is significant on a geologic scale because of the rapidity and magnitude of recent human impacts on processes operating on the Earth’s surface.
    • Many of these impacts have generated irreversible changes that exceed the small range of natural variability of the Holocene, which began 11,700 years ago.

Finding the ‘golden spike’

    • Over the years, the Anthropocene Working Group has mostly agreed that the Anthropocene is geologically real and should be formalized as an independent unit within the international scale of geologic time.
    • Its onset would be in the mid-20th century, in the 1950s, according to the global signals recorded in sediments since then.

Selection criteria

    • Twelve detailed proposals were initially submitted for different geological sections that could host this GSSP, located on five continents and situated in eight different geological environments.
    • All of them were published in 2023 in the scientific journal Anthropocene Review.
    • These papers were the main source of information for the voting members of the Anthropocene Working Group during the selection process.

And the winner is …

    • According to the results, the most relevant geological sections were located in Beppu Bay, Japan; Sihailongwan Lake, China; and Crawford Lake.
    • After a detailed analysis of the nature of their plutonium signal and a new vote, the Chinese and Canadian lake sites were finalists.
    • In the end, Crawford Lake received 61% of the votes and was chosen as the site of the GSSP for the Anthropocene epoch.

Farewell to the Holocene

    • Formalizing it precisely will help determine its meaning and use in all sciences and other academic disciplines.
    • The end of a relatively stable epoch in Earth’s history, the Holocene, will thus be recognized.

NorthStar Medical Radioisotopes Now Routinely Manufacturing High Activity Copper-67 on its Electron Accelerators for Clarity Pharmaceuticals' Therapy Clinical Programs

Retrieved on: 
Monday, June 26, 2023
Medical Devices, Clinical Trials, Biotechnology, Mining, Minerals, Radiology, Health, Pharmaceutical, Natural Resources, Oncology, US Foods, Partnership, Radiation, EAP, Radionuclide, PSA, SAR, TCTS, Secure, Cancer, Multimedia, Radiopharmaceutical, TCT, NorthStar, Patient, Microsoft Access, Prostate-specific antigen, Copper, FDA, Safety, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20230626574624/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230626574624/en/
    NorthStar has successfully produced high activity, high specific activity and high purity Cu-67 and has supplied the isotope for use in Clarity’s clinical programs as part of an agreement for exclusive supply of the radioisotope to Clarity.
  • NorthStar is the first operational commercial-scale supplier of this important therapeutic radioisotope.
  • Our efforts use the proven expertise and innovative approach demonstrated in the successful development and commercialization of other non-uranium produced radioisotopes in the US.
  • We look forward to supporting Clarity’s plans for further clinical development and commercialization of Cu-67-based therapeutic radiopharmaceuticals to improve the lives of patients with serious disease.”

POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress

Retrieved on: 
Monday, June 26, 2023
Terbium, Society, SNMMI, Radionuclide, Survival, FAP, Poster, Isotope, HEK, Actinium-225, Rare-earth element, Medical imaging

INDIANAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the publication of preclinical data from their pan-cancer, fibroblast activation protein-α (FAP)-targeted program, PNT2004, at the 2023 Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI), taking place June 24-27, 2023, in Chicago, IL.

Key Points: 
  • PNT6555, the lead candidate in the PNT2004 program, led to complete and durable tumor regression and improved survival in HEK-mFAP tumor-bearing mice when chelated to any one of the three radioisotopes studied: lutetium-177 (177Lu), actinium-225 (225Ac), and terbium-161 (161Tb).
  • Additionally, 177Lu-PNT6555 in combination with anti-PD-1 checkpoint blockade was assessed in the aggressive, immunocompetent CT26-mFAP mouse model and demonstrated a significant survival benefit compared to either treatment alone.
  • “By continuing to develop expertise in more isotopes, POINT is better positioned to create optimized next-generation radioligands, which match a ligand’s properties with the most appropriate isotope,” said Joe McCann, Ph.D., Chief Executive Officer of POINT Biopharma.
  • “The expertise to discover and develop new radioligands and advance them into clinical trials has been built into POINT.

Westinghouse Advances Key Radioisotope Technology to Fight Cancer

Retrieved on: 
Friday, June 23, 2023
Other Energy, Utilities, Alternative Energy, Biotechnology, Energy, Nuclear, Health, Pharmaceutical, Oncology, Actinium, Pennsylvania State University, Westinghouse Electric Company, Actinium-225, Food, Westinghouse, Void coefficient, Radionuclide, Uranium mining

This breakthrough will enable large-scale production of Ac-225 for the first time globally to use in advanced cancer treatments.

Key Points: 
  • This breakthrough will enable large-scale production of Ac-225 for the first time globally to use in advanced cancer treatments.
  • The existing method for producing Ac-225 is complex and the development of Ac-225 cancer treatments is limited by the availability of the radioisotope supply.
  • “Our new approach can significantly increase global radioisotope production capacity using Westinghouse technology in reactors around the world,” says Tarik Choho, President of Westinghouse Nuclear Fuel.
  • Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world's operating nuclear plants.

Serva Energy Discovers Promising New Way to Produce Cancer-killing Actinium-225 Isotope

Retrieved on: 
Thursday, June 22, 2023
Actinium, U.S. Department of Defense Strategy for Operating in Cyberspace, Radionuclide, Alpha, TAT, Radiopharmaceutical, Radiology, Cancer, Actinium-225, Biomedical Research, Research, Multimedia, Nuclear medicine, Mayo Clinic, Radiochemistry, Isotope, Rare-earth element, Uranium mining, Medical imaging

"What's really exciting about this innovation is the potential to save lives," said Ian Horvath, founder and CEO of Serva Energy.

Key Points: 
  • "What's really exciting about this innovation is the potential to save lives," said Ian Horvath, founder and CEO of Serva Energy.
  • "Actinium-225 is the miracle isotope that can open the doors to the cancer treatments we've been wishing for.
  • The isotope used in this research was supplied by the U.S. Department of Energy Isotope Program, managed by the Office of Isotope R&D Production.
  • Serva Energy is a nuclear technology company revolutionizing the way radioisotopes and nuclear fuels are produced—serving the world critical cancer treatments and a safe carbon-free transition to a clean energy future.

IBC Launches Full Range of Best-in-Class Molecular Recognition Technology™ (MRT™) Flowsheets for Highly Selective Separations of Key Radionuclides and Preparation of Novel Chelating Agents for Radionuclide Incorporation into Radiopharmaceuticals

Retrieved on: 
Tuesday, June 20, 2023
Molecular recognition, Caesium, IBC, Metal, Radionuclide, Strontium, Ligand, Regeneration, Multimedia, Process flowsheeting, Radiopharmaceutical, EDS, Noetics, Izatt, Chelation, Elemental analysis, Mining, Wiley-VCH, Green chemistry, Conference, Peptide, Medical imaging, Palladium, Engineered wood, Fine chemical, Uranium mining, Seawater

IBC works closely with each customer to design, build, and commission a customized separation system to meet their needs.

Key Points: 
  • IBC works closely with each customer to design, build, and commission a customized separation system to meet their needs.
  • IBC is an award-winning manufacturer and supplier of highly selective separations products, engineered systems and processes based on Molecular Recognition Technology™ (MRT™.)
  • Industrial Applications of Molecular Recognition Technology to Green Chemistry Separations of Platinum Group Metals and Selective Removal of Metal Impurities from Process Streams.
  • Green Chemistry Molecular Recognition Processes Applied to Metal Separations in Ore Beneficiation, Element Recycling, Metal Remediation, and Elemental Analysis.

IBC Launches Full Range of Best-in-Class Molecular Recognition Technology™ (MRT™) Flowsheets for Highly Selective Separations of Key Radionuclides and Preparation of Novel Chelating Agents for Radionuclide Incorporation into Radiopharmaceuticals

Retrieved on: 
Tuesday, June 20, 2023
Molecular recognition, Caesium, IBC, Metal, Radionuclide, Strontium, Ligand, Regeneration, Process flowsheeting, Radiopharmaceutical, EDS, Noetics, Izatt, Chelation, Elemental analysis, Mining, Wiley-VCH, Green chemistry, Conference, Peptide, Medical imaging, Palladium, Engineered wood, Fine chemical, Uranium mining, Seawater

IBC works closely with each customer to design, build, and commission a customized separation system to meet their needs.

Key Points: 
  • IBC works closely with each customer to design, build, and commission a customized separation system to meet their needs.
  • IBC is an award-winning manufacturer and supplier of highly selective separations products, engineered systems and processes based on Molecular Recognition Technology™ (MRT™.)
  • Industrial Applications of Molecular Recognition Technology to Green Chemistry Separations of Platinum Group Metals and Selective Removal of Metal Impurities from Process Streams.
  • Green Chemistry Molecular Recognition Processes Applied to Metal Separations in Ore Beneficiation, Element Recycling, Metal Remediation, and Elemental Analysis.

NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer

Retrieved on: 
Monday, June 19, 2023
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Executive, University, Radionuclide, London Business School, Health care, McKinsey & Company, Health technology, McDonough School of Business, Business, MBA, Multimedia, Radiopharmaceutical, Royal Navy, Bachelor of Science, Engineering physics, Science, Georgetown University, NorthStar, Nuclear medicine, AlixPartners, CDMO, Patient, Leibniz University Hannover, Engineering, Honor, United Kingdom, Commander of the Navy (Sri Lanka), Growth, Nuclear, Management, Mallinckrodt, Economics

NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., as its new President and Chief Executive Officer (CEO) effective Monday, June 26, 2023.

Key Points: 
  • NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., as its new President and Chief Executive Officer (CEO) effective Monday, June 26, 2023.
  • Dr. Scholz joined NorthStar in 2021, and was promoted to President and Chief Operating Officer (COO) in 2022.
  • Mr. Stephen Merrick, who joined NorthStar in 2016 and has been CEO since 2018, will assume the role of Executive Chairman.
  • Mr. Merrick joined NorthStar in 2016 and was appointed as President and Chief Executive Officer of NorthStar in September 2018.

ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer

Retrieved on: 
Tuesday, June 13, 2023
NOVA, ITM, Pharmaceutical Advertising Advisory Board, Therapy, TUM, Radionuclide, FRM, Institute of technology, Radiopharmaceutical, Cancer, Quality of life, Medicine, Research, Advisory board, Minister for Federal Affairs (New South Wales), Vetter Pharma, Nuclear medicine, Free, State Chancellery of Latvia, Patient, Laboratory, Supervisory board, Bavaria, Knowledge, Growth, Health, Munich Airport, Isotope, Automation, IAZ, Technical University of Munich, Pharmaceutical industry, State

ITM’s new facility is the world’s largest production site of lutetium-177, an innovative medical isotope used in targeted cancer therapies.

Key Points: 
  • ITM’s new facility is the world’s largest production site of lutetium-177, an innovative medical isotope used in targeted cancer therapies.
  • Once the new NOVA production facility is fully operational, ITM will increase its capacity to supply clinics, pharmaceutical partners and its own drug pipeline tenfold.
  • The world's largest lutetium-177 production facility for targeted radionuclide therapies against cancer, opened by ITM, is therefore an important milestone - both for the company, the research and production location of Bavaria as a whole and, of course, the patients.
  • “As a local member of parliament, I am particularly pleased that the production facility is being built here in Neufahrn near Freising.